1cBio

Phase 1/2

San Francisco Bay Area, United StatesFounded 20221cbio.com

1cBio is a private, preclinical-to-clinical stage biopharmaceutical company leveraging a rational discovery platform to convert transformative scientific ideas into future medicines. Its strategy centers on defined, clinically validated mechanisms of action, aiming to treat disease while preempting resistance. The company's pipeline includes a partnered Phase 1/2a program for hypophosphatasia and a potentially best-in-class, selective PARP1 inhibitor for oncology, supported by a leadership team with a proven track record of advancing drugs to market.

Founded

2022

Focus

Small Molecules

AI Company Overview

Technology Platform

A rational discovery platform integrating medicinal chemistry and translational sciences to develop precision small molecule therapies targeting validated mechanisms of action, with a focus on preempting treatment resistance.

Opportunities

The oral HPP drug OC-1/ALE1 addresses a clear need for patient-friendly alternatives to injectable enzyme therapy.

In oncology, the selective PARP1 inhibitor OC-3 targets a large market with a potential best-in-class safety profile, enabling broader use and novel combinations.

The brain-penetrant CDK7 inhibitor program opens a high-value niche in treating breast cancer brain metastases.

Risk Factors

High risk of clinical failure for early-stage assets.

Dependence on partnerships for funding and development of key programs.

Intense competition in the PARP and CDK7 inhibitor spaces requires clear demonstration of superior efficacy or safety.

Competitive Landscape

Faces competition from Alexion's Strensiq in HPP and from established pan-PARP inhibitors (Lynparza, Zejula, Talzenna) and other selective PARP1 developers in oncology. Differentiation hinges on OC-1's oral dosing and OC-3's potential for reduced hematological toxicity due to PARP1 selectivity.